See more : Dowa Holdings Co., Ltd. (DWMNF) Income Statement Analysis – Financial Results
Complete financial analysis of Siemens Healthineers AG (SMMNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Siemens Healthineers AG, a leading company in the Medical – Devices industry within the Healthcare sector.
- G3 VRM Acquisition Corp. (GGGVR) Income Statement Analysis – Financial Results
- Marston’s PLC (MARZF) Income Statement Analysis – Financial Results
- Voya Financial, Inc. (VOYA) Income Statement Analysis – Financial Results
- Banque Saudi Fransi (1050.SR) Income Statement Analysis – Financial Results
- HeartCore Enterprises, Inc. (HTCR) Income Statement Analysis – Financial Results
Siemens Healthineers AG (SMMNY)
About Siemens Healthineers AG
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.36B | 21.68B | 21.71B | 18.00B | 14.46B | 14.52B | 13.43B | 13.80B | 13.55B | 12.94B |
| Cost of Revenue | 13.90B | 13.97B | 13.58B | 11.05B | 8.88B | 8.72B | 7.96B | 8.03B | 8.08B | 7.87B |
| Gross Profit | 8.47B | 7.71B | 8.14B | 6.95B | 5.58B | 5.80B | 5.47B | 5.76B | 5.47B | 5.07B |
| Gross Profit Ratio | 37.87% | 35.56% | 37.47% | 38.63% | 38.59% | 39.92% | 40.72% | 41.77% | 40.36% | 39.19% |
| Research & Development | 1.92B | 1.87B | 1.79B | 1.55B | 1.34B | 1.33B | 1.28B | 1.25B | 1.15B | 1.06B |
| General & Administrative | 3.68B | 3.61B | 3.41B | 2.82B | 2.28B | 2.21B | 2.15B | 2.22B | 2.21B | 2.11B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.68B | 3.61B | 3.41B | 2.82B | 2.28B | 2.21B | 2.15B | 2.22B | 2.21B | 2.11B |
| Other Expenses | 2.87B | 103.00M | 20.00M | 32.00M | 15.00M | -42.00M | 73.00M | -3.00M | -1.00M | -58.00M |
| Operating Expenses | 8.47B | 5.58B | 5.21B | 4.40B | 3.64B | 3.50B | 3.51B | 3.47B | 3.35B | 3.11B |
| Cost & Expenses | 22.36B | 19.55B | 18.79B | 15.44B | 12.52B | 12.22B | 11.47B | 11.51B | 11.43B | 10.97B |
| Interest Income | 119.00M | 89.00M | 48.00M | 33.00M | 53.00M | 38.00M | 41.00M | 12.00M | 14.00M | 19.00M |
| Interest Expense | 476.00M | 296.00M | 118.00M | 83.00M | 76.00M | 123.00M | 205.00M | 267.00M | 216.00M | 117.00M |
| Depreciation & Amortization | 1.22B | 1.56B | 1.34B | 1.04B | 815.00M | 620.00M | 530.00M | 572.00M | 591.00M | 563.00M |
| EBITDA | 4.22B | 3.78B | 4.26B | 3.53B | 2.85B | 2.94B | 2.53B | 2.82B | 2.73B | 2.56B |
| EBITDA Ratio | 18.88% | 17.44% | 19.62% | 19.53% | 19.44% | 20.22% | 18.87% | 20.90% | 20.12% | 19.76% |
| Operating Income | 0.00 | 2.13B | 2.92B | 2.48B | 2.00B | 2.32B | 1.96B | 2.29B | 2.12B | 1.96B |
| Operating Income Ratio | 0.00% | 9.84% | 13.44% | 13.76% | 13.80% | 15.95% | 14.60% | 16.60% | 15.63% | 15.17% |
| Total Other Income/Expenses | 2.52B | -205.00M | -20.00M | -60.00M | -41.00M | -103.00M | -162.00M | -246.00M | -199.00M | -87.00M |
| Income Before Tax | 2.52B | 1.93B | 2.80B | 2.40B | 1.95B | 2.19B | 1.80B | 2.04B | 1.92B | 1.88B |
| Income Before Tax Ratio | 11.28% | 8.89% | 12.89% | 13.36% | 13.51% | 15.11% | 13.40% | 14.82% | 14.16% | 14.50% |
| Income Tax Expense | 564.00M | 403.00M | 746.00M | 658.00M | 532.00M | 607.00M | 515.00M | 600.00M | 590.00M | 584.00M |
| Net Income | 1.94B | 1.51B | 2.04B | 1.73B | 1.41B | 1.57B | 1.27B | 1.38B | 1.31B | 1.28B |
| Net Income Ratio | 8.68% | 6.96% | 9.39% | 9.60% | 9.76% | 10.79% | 9.42% | 10.00% | 9.68% | 9.87% |
| EPS | 0.00 | 1.34 | 1.82 | 1.57 | 1.41 | 1.57 | 0.63 | 0.69 | 0.66 | 0.64 |
| EPS Diluted | 0.00 | 1.34 | 1.81 | 1.56 | 1.41 | 1.57 | 0.63 | 0.69 | 0.66 | 0.64 |
| Weighted Avg Shares Out | 0.00 | 1.13B | 1.12B | 1.10B | 1.00B | 999.25M | 2.00B | 2.00B | 2.00B | 2.00B |
| Weighted Avg Shares Out (Dil) | 0.00 | 1.12B | 1.13B | 1.10B | 1.00B | 1.00B | 2.00B | 2.00B | 2.00B | 2.00B |
Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy
Siemens Healthineers Offers Imaging-Driven Upside For Patient Investors
Siemens Healthineers AG (SEMHF) Q4 2024 Earnings Call Transcript
Siemens Healthineers meets full-year earnings forecast
Siemens Healthineers: My Current Pick In Medtech Ahead Of Q4 2024
Together with Siemens Healthineers, Varian Highlights Software and Imaging Innovations to Enable Personalized Patient Care at ASTRO 2024
Fertility-related stocks are becoming more attractive, Barclays says
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers AG (SEMHF) Q3 2024 Earnings Call Transcript
AI in Medical Diagnostics Market Insights and Forecast, 2024-2033 - Top Ten Competitors Account for 56.02% of the Total Revenue, Led by Siemens Healthineers, Followed Closely by Merative L.P.
Source: https://incomestatements.info
Category: Stock Reports